Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Abhinav SharmaPedro MarquesBrendon L NeuenRobert A FletcherApril E HebertWally RapattoniFernando G AngClare ArnottAdeera LevinSubodh VermaVlado PerkovicKenneth W MahaffeyPublished in: Diabetes, obesity & metabolism (2023)